Cargando…

Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma

Lenvatinib was recently approved as a novel first-line molecular targeted agent (MTA) for treating hepatocellular carcinoma (HCC). The importance of relative dose intensity (RDI) has been shown in the treatment of various types of cancers. However, RDI may not accurately reflect the treatment intens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eso, Yuji, Nakano, Shigeharu, Mishima, Masako, Arasawa, Soichi, Iguchi, Eriko, Nakamura, Fumiyasu, Takeda, Haruhiko, Takai, Atsushi, Takahashi, Ken, Taura, Kojiro, Seno, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016578/ https://www.ncbi.nlm.nih.gov/pubmed/31877859 http://dx.doi.org/10.3390/cancers12010049

Ejemplares similares

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
por: Eso, Yuji, et al.
Publicado: (2021)

Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencing
por: Nakamura, Fumiyasu, et al.
Publicado: (2022)

DNA methyltransferase 3B plays a protective role against hepatocarcinogenesis caused by chronic inflammation via maintaining mitochondrial homeostasis
por: Iguchi, Eriko, et al.
Publicado: (2020)

Author Correction: DNA methyltransferase 3B plays a protective role against hepatocarcinogenesis caused by chronic inflammation via maintaining mitochondrial homeostasis
por: Iguchi, Eriko, et al.
Publicado: (2021)

Evolutional transition of HBV genome during the persistent infection determined by single-molecule real-time sequencing
por: Arasawa, Soichi, et al.
Publicado: (2023)

Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma
por: Eso, Yuji, et al.
Publicado: (2019)

Recent Advances in Immunotherapy for Hepatocellular Carcinoma
por: Nakano, Shigeharu, et al.
Publicado: (2020)

Genetic Landscape of Multistep Hepatocarcinogenesis
por: Takeda, Haruhiko, et al.
Publicado: (2022)

Single-molecular real-time deep sequencing reveals the dynamics of multi-drug resistant haplotypes and structural variations in the hepatitis C virus genome
por: Yamashita, Taiki, et al.
Publicado: (2020)

Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid Arthritis
por: Yoshiji, Satoshi, et al.
Publicado: (2018)

Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers
por: Eso, Yuji, et al.
Publicado: (2019)

Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication
por: Oe, Natsumi, et al.
Publicado: (2022)

Expansion of viral variants associated with immune escape and impaired virion secretion in patients with HBV reactivation after resolved infection
por: Inuzuka, Tadashi, et al.
Publicado: (2018)

Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers
por: Eso, Yuji, et al.
Publicado: (2020)

Hepatitis-associated Aplastic Anemia with Rapid Progression of Liver Fibrosis Due to Repeated Hepatitis
por: Sawada, Kenji, et al.
Publicado: (2019)

Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives
por: Ueno, Masayuki, et al.
Publicado: (2022)

Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment
por: Mizokami, Ken, et al.
Publicado: (2022)

Acute Anorectal Thrombophlebitis Caused by a Protein C Deficiency
por: Eso, Yuji, et al.
Publicado: (2017)

Post-COVID-19 interstitial lung disease presenting with profound hypoxemia: Report of three cases demonstrating a good response to high-dose corticosteroid therapy
por: Uemasu, Kiyoshi, et al.
Publicado: (2022)

Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study
por: Yasuda, Yuto, et al.
Publicado: (2022)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Management of severe hypertension due to lenvatinib in patients with advanced thymic carcinoma: A case report
por: Matsumoto, Kinnosuke, et al.
Publicado: (2022)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
por: Fujimoto, Kana, et al.
Publicado: (2022)

Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion
por: Takeda, Haruhiko, et al.
Publicado: (2019)

C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2022)

Choledochoduodenal Fistula during Chemotherapy with Brentuximab Vedotin for Methotrexate-associated Lymphoproliferative Disorder
por: Eso, Yuji, et al.
Publicado: (2018)

Advances and Future Directions in Hepatobiliary Malignancies
por: Taura, Kojiro
Publicado: (2023)

Aluminium Gauze Reduces SARS-CoV-2 Viral Load in Non-Woven Masks Worn by Patients with COVID-19
por: Yasuda, Yuto, et al.
Publicado: (2022)

Targeting Angiogenesis for Advanced Hepatocellular Carcinoma
por: Eso, Yuji
Publicado: (2020)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report
por: Eso, Yuji, et al.
Publicado: (2017)

Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer
por: Uchida, Taisuke, et al.
Publicado: (2019)

Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib
por: Taylor, Matthew H., et al.
Publicado: (2021)

Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases
por: Takeda, Haruhiko, et al.
Publicado: (2012)

Whole-exome sequencing for a more accurate diagnosis of intraductal papillary neoplasms of the bile duct
por: Matsumori, Tomoaki, et al.
Publicado: (2021)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

Anti-integrin αvβ6 autoantibodies in patients with primary sclerosing cholangitis
por: Yoshida, Hiroyuki, et al.
Publicado: (2023)

Rapid disease progression after discontinuation of lenvatinib in thyroid cancer
por: Yamazaki, Haruhiko, et al.
Publicado: (2020)

Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_31d497gmb1qvulhiok8r1r936e